Jounce Therapeutics, Inc.
JNCENASDAQHealthcare
$1.88
+$0.00(+0.00%)
Market Cap$98954740
P/E Ratio—
52W High$5.37
52W Low$0.5773
Jounce Therapeutics, Inc. (JNCE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
JNCE · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2023Report Date: May 4, 2023EPS Actual
-$0.72
Est. -$0.72 · +0.0%
Revenue
—
Est. $0.04B
Fiscal Period
Q2 FY2023
FY ends December
Report Date
May 4, 2023
After Market Close
✓ 3-Quarter EPS Beat Streak
JNCE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2024 | Mar 8, 2024 | — | — | — | — | — | — |
| ◌ Q4 FY2023 | Nov 8, 2023 | — | — | — | — | — | — |
| ◌ Q3 FY2023 | Aug 2, 2023 | -$0.68 | — | — | — | — | — |
| — Q2 FY2023 | May 4, 2023 | -$0.72 | -$0.72 | +0.0% | — | $0.04B | — |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.99 | — | $0.08B | — | — |
| ▲ Q4 FY2022 | Nov 10, 2022 | -$0.64 | -$0.60 | +6.3% | — | — | — |
| ▲ Q3 FY2022 | Aug 4, 2022 | -$0.68 | -$0.65 | +4.4% | — | — | — |
| ▼ Q2 FY2022 | May 5, 2022 | -$0.57 | -$0.72 | -26.3% | $0.00B | $0.00B | -100.0% |
Q1 FY2024
Mar 8, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 8, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 2, 2023
EPS Actual
—
EPS Est.
-$0.68
EPS Surpr.
—
Revenue
—
Q2 FY2023
May 4, 2023
EPS Actual
-$0.72
EPS Est.
-$0.72
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2022
Dec 31, 2022
EPS Actual
$0.99
EPS Est.
—
EPS Surpr.
—
Revenue
$0.08B
Q4 FY2022
Nov 10, 2022Beat
EPS Actual
-$0.60
EPS Est.
-$0.64
EPS Surpr.
+6.3%
Revenue
—
Q3 FY2022
Aug 4, 2022Beat
EPS Actual
-$0.65
EPS Est.
-$0.68
EPS Surpr.
+4.4%
Revenue
—
Q2 FY2022
May 5, 2022Miss
EPS Actual
-$0.72
EPS Est.
-$0.57
EPS Surpr.
-26.3%
Revenue
$0.00B
No analyst estimates available for JNCE.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2023 | May 4, 2023 | +0.0% | $1.88 | $1.88 | +0.00% |
| — Q4 FY2022 | Dec 31, 2022 | — | $1.11 | $1.09 | -1.80% |
| ▲ Q4 FY2022 | Nov 10, 2022 | +6.3% | $1.99 | $1.17 | -41.21% |
| ▲ Q3 FY2022 | Aug 4, 2022 | +4.4% | $3.37 | $3.62 | +7.42% |
| ▼ Q2 FY2022 | May 5, 2022 | -26.3% | $5.22 | $4.86 | -6.90% |
| — Q4 FY2021 | Dec 31, 2021 | — | $8.11 | $8.35 | +2.96% |
| ▼ Q4 FY2021 | Nov 4, 2021 | -47.5% | $9.64 | $9.61 | -0.31% |
| ▲ Q3 FY2021 | Aug 5, 2021 | +79.0% | $5.11 | $5.20 | +1.76% |
Q2 FY2023+0.00%
Report Date
May 4, 2023
EPS Beat/Miss
+0.0%
Price Before
$1.88
Price After
$1.88
Q4 FY2022-1.80%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$1.11
Price After
$1.09
Q4 FY2022-41.21%
Report Date
Nov 10, 2022
EPS Beat/Miss
+6.3%
Price Before
$1.99
Price After
$1.17
Q3 FY2022+7.42%
Report Date
Aug 4, 2022
EPS Beat/Miss
+4.4%
Price Before
$3.37
Price After
$3.62
Q2 FY2022-6.90%
Report Date
May 5, 2022
EPS Beat/Miss
-26.3%
Price Before
$5.22
Price After
$4.86
Q4 FY2021+2.96%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$8.11
Price After
$8.35
Q4 FY2021-0.31%
Report Date
Nov 4, 2021
EPS Beat/Miss
-47.5%
Price Before
$9.64
Price After
$9.61
Q3 FY2021+1.76%
Report Date
Aug 5, 2021
EPS Beat/Miss
+79.0%
Price Before
$5.11
Price After
$5.20
Avg Beat Reaction-8.01%
Avg Miss Reaction-3.60%
Beat Rate4 / 8 quarters
Largest Move-41.21% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: JNCE ends December
Jounce Therapeutics, Inc. (JNCE) most recently reported earnings on May 4, 2023 for Q2 FY2023, posting EPS of $-0.72 (in line with the analyst consensus of $-0.72). JNCE has beaten EPS estimates for 3 consecutive quarters. The next JNCE earnings date is expected around September 1, 2026.
Each quarter, investors track JNCE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. JNCE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
JNCE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
JNCE earnings · 4 questionsJounce Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. JNCE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; JNCE historically reports after market close (AMC).
JNCE earnings datewhen is JNCE earningsJNCE next earnings datewhen does JNCE report earningsJNCE earnings calendar
▸ Source: FMP · Jounce Therapeutics, Inc. SEC filings · US GAAP · Jounce Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026